Certain Meds Not Cost-Effective for First-Line Therapy of T2DM
Compared with metformin, SGLT2 inhibitors, GLP-1 receptor agonists cost more for treatment in drug-naive patients with type 2 diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.